Shares of Acorda Therapeutics (ACOR) surged over 90% on Tuesday because of a milestone payment worth $15M from Biogen (BIIB).
Under the license agreement with Biogen, based on Biogen’s ex-U.S. net sales of Fampyra exceeding $100 million over the four consecutive quarters ending with the third quarter of 2020. Acorda Therapeutics will retain approximately $14 million of the milestone payment net of their payment obligations to another party. Acorda expects to receive the payment by the end of October 2020.
Should you invest in Acorda Therapeutics (ACOR)?
Shares of Acorda Therapeutics (ACOR) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the next of years. The majority of the metrics point to this investment being highly attractive.